Medicare Enrolled

Dr. Maydee Rosario-Reglero, M.D.

Pulmonary Disease · Waco, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
7003 WOODWAY DR, Waco, TX 76712
2547411688
In practice since 2005 (20 years)
NPI: 1437130077 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rosario-Reglero from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rosario-Reglero? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rosario-Reglero

Dr. Maydee Rosario-Reglero is a pulmonary disease specialist in Waco, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rosario-Reglero performed 2,037 Medicare services across 1,673 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rosario-Reglero received a total of $11,093 from 33 pharmaceutical and/or device companies across 295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rosario-Reglero is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 17% volume in TX $11,093 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,037
Medicare services
Top 17% in TX for pulmonary disease
1,673
Unique beneficiaries
$59
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~102 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Pulmonary gas exchange test
A test to examine how well the lungs exchange gases.
259 $40 $155
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
256 $61 $213
Lung volume test using sensors
A test that measures the amount of air in the lungs using sensors.
246 $39 $151
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
211 $90 $313
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
147 $29 $174
Chest X-ray, 2 views
An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall.
138 $25 $80
Critical care, first 30-74 min
Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient.
126 $159 $805
Expiratory airflow and volume test
A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume.
122 $20 $102
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
108 $49 $211
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
103 $92 $309
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
86 $61 $214
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
61 $121 $479
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
58 $80 $314
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
32 $10 $73
Health risk assessment administration and interpretation
This procedure involves administering a health risk assessment to a patient and interpreting the results.
30 $2 $10
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
30 $131 $599
Methylprednisolone injection, up to 125 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg.
13 $4 $8
Exercise-induced lung stress test
A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising.
11 $24 $105
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$11,093
Total received (2018-2024)
Avg $1,585/year across 7 years
Top 18% in TX for pulmonary disease
33
Companies
295
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,415 (57.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,678 (42.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$989
2023
$347
2022
$438
2021
$386
2020
$4,699
2019
$1,538
2018
$2,696

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Intuitive Surgical, Inc.
$4,791
AstraZeneca Pharmaceuticals LP
$1,857
Covidien LP
$899
GlaxoSmithKline, LLC.
$572
GENZYME CORPORATION
$441
Regeneron Healthcare Solutions, Inc.
$330
Boehringer Ingelheim Pharmaceuticals, Inc.
$265
Mylan Specialty L.P.
$256
Actelion Pharmaceuticals US, Inc.
$221
Novartis Pharmaceuticals Corporation
$195
Sunovion Pharmaceuticals Inc.
$175
Philips Electronics North America Corporation
$144
Edwards Lifesciences Corporation
$107
Grifols USA, LLC
$93
SANOFI-AVENTIS U.S. LLC
$89
Electromed, Inc.
$85
Circassia Pharmaceuticals Inc
$71
Phathom Pharmaceuticals, Inc.
$59
CSL Behring
$58
PFIZER INC.
$52
Genentech USA, Inc.
$44
Mallinckrodt Enterprises LLC
$40
Mallinckrodt LLC
$38
Mayne Pharma Inc.
$37
Gilead Sciences, Inc.
$34
Merck Sharp & Dohme Corporation
$29
Bayer HealthCare Pharmaceuticals Inc.
$21
Alexion Pharmaceuticals, Inc.
$21
ANI Pharmaceuticals, Inc.
$17
Shire North American Group Inc
$14
United Therapeutics Corporation
$13
Amgen Inc.
$13
E.R. Squibb & Sons, L.L.C.
$12
Top 3 companies account for 68.0% of total payments
Associated products mentioned in payments ›
ACTHAR · AIRSUPRA · ANORO · ASMANEX · Adempas · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHANTIX · DORYX · DUPIXENT · Da Vinci Surgical System · Dymista · ELIQUIS · Esbriet · FASENRA · GLASSIA · HemoSphere · LONHALA MAGNAIR · Letairis · NIOX VERO · NUCALA · OFEV · OPSUMIT MACITENTAN · PAXLOVID · PREVNAR - 13 · PURIFIED CORTROPHIN GEL · Prolastin-C · Prolastin-C Liquid · Respiratoriy Care Undiv · SMARTVEST · SOLIRIS · STIOLTO RESPIMAT · SYMBICORT · SuperDimension · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · UPTRAVI · UTIBRON · VOQUEZNA · Wellcentive Undiv · XOLAIR · Xolair · Yupelri · Zemaira · inCourage · superDimension
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (58%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $545 per 100 Medicare services performed
Looking for a pulmonary disease specialist in Waco?
Compare pulmonary diseases in the Waco area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
5
Per 100K population
1.9
County median income
$63,888
Nearest hospital
ASCENSION PROVIDENCE
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Rosario-Reglero is a clinical cardiology specialist, with above-average Medicare volume (top 17% in TX), with low-engagement industry engagement in the top 18% of TX peers, with 20 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Rosario-Reglero experienced with pulmonary gas exchange test?
Based on Medicare claims data, Dr. Rosario-Reglero performed 259 pulmonary gas exchange test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rosario-Reglero receive payments from pharmaceutical companies?
Yes. Dr. Rosario-Reglero received a total of $11,093 from 33 companies across 295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rosario-Reglero's costs compare to other pulmonary diseases in Waco?
Dr. Rosario-Reglero's average Medicare payment per service is $59. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rosario-Reglero) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →